Literature DB >> 16621883

Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review.

P Brindle1, A Beswick, T Fahey, S Ebrahim.   

Abstract

OBJECTIVE: To determine the accuracy of assessing cardiovascular disease (CVD) risk in the primary prevention of CVD and its impact on clinical outcomes.
DESIGN: Systematic review. DATA SOURCES: Published studies retrieved from Medline and other databases. Reference lists of identified articles were inspected for further relevant articles. SELECTION OF STUDIES: Any study that compared the predicted risk of coronary heart disease (CHD) or CVD, with observed 10-year risk based on the widely recommended Framingham methods (review A). Randomised controlled trials examining the effect on clinical outcomes of a healthcare professional assigning a cardiovascular risk score to people predominantly without CVD (review B). REVIEW
METHODS: Data were extracted on the ratio of the predicted to the observed 10-year risk of CVD and CHD (review A), and on cardiovascular or coronary fatal or non-fatal events, risk factor levels, absolute cardiovascular or coronary risk, prescription of risk-reducing drugs and changes in health-related behaviour (review B).
RESULTS: 27 studies with data from 71,727 participants on predicted and observed risk for either CHD or CVD were identified. For CHD, the predicted to observed ratios ranged from an underprediction of 0.43 (95% CI 0.27 to 0.67) in a high-risk population to an overprediction of 2.87 (95% CI 1.91 to 4.31) in a lower-risk population. In review B, four randomised controlled trials confined to people with hypertension or diabetes found no strong evidence that a cardiovascular risk assessment performed by a clinician improves health outcomes.
CONCLUSION: The performance of the Framingham risk scores varies considerably between populations and evidence supporting the use of cardiovascular risk scores for primary prevention is scarce.

Entities:  

Mesh:

Year:  2006        PMID: 16621883      PMCID: PMC1861278          DOI: 10.1136/hrt.2006.087932

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  30 in total

1.  Controlled trial of effect of documented cardiovascular risk scores on prescribing.

Authors:  L M L Hall; R T Jung; G P Leese
Journal:  BMJ       Date:  2003-02-01

2.  Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts.

Authors:  Hans-Werner Hense; Helmut Schulte; Hannelore Löwel; Gerd Assmann; Ulrich Keil
Journal:  Eur Heart J       Date:  2003-05       Impact factor: 29.983

Review 3.  Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians.

Authors:  Stacey Sheridan; Michael Pignone; Cynthia Mulrow
Journal:  J Gen Intern Med       Date:  2003-12       Impact factor: 5.128

4.  Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals.

Authors:  Philip Greenland; Laurie LaBree; Stanley P Azen; Terence M Doherty; Robert C Detrano
Journal:  JAMA       Date:  2004-01-14       Impact factor: 56.272

5.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.

Authors:  R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

6.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Eur Heart J       Date:  2003-09       Impact factor: 29.983

7.  Risk functions for prediction of cardiovascular disease in elderly Australians: the Dubbo Study.

Authors:  Leon A Simons; Judith Simons; Yechiel Friedlander; John McCallum; Latha Palaniappan
Journal:  Med J Aust       Date:  2003-02-03       Impact factor: 7.738

8.  Framingham Heart Study risk equation predicts first cardiovascular event rates in New Zealanders at the population level.

Authors:  Richard Milne; Gregory Gamble; Gary Whitlock; Rodney Jackson
Journal:  N Z Med J       Date:  2003-11-07

9.  Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study.

Authors:  J P Empana; P Ducimetière; D Arveiler; J Ferrières; A Evans; J B Ruidavets; B Haas; J Yarnell; A Bingham; P Amouyel; J Dallongeville
Journal:  Eur Heart J       Date:  2003-11       Impact factor: 29.983

10.  Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study.

Authors:  Peter Brindle; Jonathan Emberson; Fiona Lampe; Mary Walker; Peter Whincup; Tom Fahey; Shah Ebrahim
Journal:  BMJ       Date:  2003-11-29
View more
  118 in total

1.  Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial.

Authors:  Tazeen H Jafar; Muhammad Islam; Rasool Bux; Neil Poulter; Juanita Hatcher; Nish Chaturvedi; Shah Ebrahim; Peter Cosgrove
Journal:  Circulation       Date:  2011-09-19       Impact factor: 29.690

2.  Sex differences in the association of Framingham Cardiac Risk Score with cognitive decline in community-dwelling elders without clinical heart disease.

Authors:  Gail A Laughlin; Linda K McEvoy; Denise von Mühlen; Lori B Daniels; Donna Kritz-Silverstein; Jaclyn Bergstrom; Kevin Cummins; Claudia Der-Martirosian; Simerjot K Jassal; Elizabeth Barrett-Connor
Journal:  Psychosom Med       Date:  2011-09-23       Impact factor: 4.312

3.  Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists.

Authors:  Ricky D Turgeon; Todd J Anderson; Jean Grégoire; Glen J Pearson
Journal:  Can Pharm J (Ott)       Date:  2015-01

4.  The value of risk scores.

Authors:  J S Jürgensen
Journal:  Heart       Date:  2006-06-06       Impact factor: 5.994

5.  Cardiovascular risk estimation: important but may be inaccurate.

Authors:  Vishnu Madhok; Tom Fahey
Journal:  BMJ       Date:  2006-05-31

6.  Can non-physician health-care workers assess and manage cardiovascular risk in primary care?

Authors:  Dele O Abegunde; Bakuti Shengelia; Anne Luyten; Alexandra Cameron; Francesca Celletti; Sania Nishtar; Vasu Pandurangi; Shanthi Mendis
Journal:  Bull World Health Organ       Date:  2007-06       Impact factor: 9.408

7.  Which risk engines are best to assess CVD risk in diabetes?

Authors:  Parinya Chamnan; Rebecca K Simmons; Simon J Griffin
Journal:  Nat Rev Endocrinol       Date:  2010-02       Impact factor: 43.330

8.  Development of a cardiovascular risk score for use in low- and middle-income countries.

Authors:  Stella Aslibekyan; Hannia Campos; Eric B Loucks; Crystal D Linkletter; Jose M Ordovas; Ana Baylin
Journal:  J Nutr       Date:  2011-05-11       Impact factor: 4.798

9.  Discrepancies between two lipid-lowering guidelines for CVD prevention in seemingly healthy individuals-case study Lebanon.

Authors:  Hussain Ali Isma'eel; Bernard Harbieh; Hani Tamim; Lara Nasreddine; Farah Naja; Abla Sibai; Nada Adra; Kamal Badr; Nahla Hwalla
Journal:  Cardiovasc Diagn Ther       Date:  2013-09

10.  Adherence to preventive statin therapy according to socioeconomic position.

Authors:  Helle Wallach-Kildemoes; Morten Andersen; Finn Diderichsen; Theis Lange
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.